Lupin Limited settles patent dispute with Astellas Pharma over Mirabegron, paying $90 million and ongoing fees, securing US sales and improving revenue visibility through mid-FY28.
Lupin Limited settles patent dispute with Astellas Pharma over Mirabegron, paying $90 million and ongoing fees, securing US sales and improving revenue visibility through mid-FY28.